Table 5.
Country | Ciprofloxacin | Co‐amoxiclav | Erythromycin | Gentamicin | Tetracyclines | Method used | Quantitative (Q) or categorical (SIR) | Interpretive criteria |
---|---|---|---|---|---|---|---|---|
Austria | ● | ● | ● | ● | DL | Q | Interpreted by ECDC. EUCAST ECOFF (CIP, ERY, GEN, TET), CA‐SFM CBP 2015 (AMC) | |
Cyprus | ● | ● | ● | DD | Q | Interpreted by ECDC, as for Austria | ||
Denmark | ● | ● | ● | ● | DL | Q | Interpreted by ECDC, as for Austria | |
Estonia | ● | ● | ● | DD | Q | Interpreted by ECDC, as for Austria | ||
Finland | ● | ● | ● | DD/DLG | Q | Interpreted by ECDC, as for Austria | ||
France | ● | ● | ● | ● | ● | DD | SIR | EUCAST CBP 2013 (CIP, ERY, TET), CA‐SFM CBP 2015 (AMC, GEN) |
Iceland | ● | ● | DD/DLG | SIR | EUCAST CBP 2015 | |||
Italy | ● | ● | ● | DD | Q | Interpreted by ECDC, as for Austria | ||
Lithuania | ● | ● | ● | DD | SIR | EUCAST CBP 2015 | ||
Luxembourg | ● | ● | ● | ● | DD/DLG | Q | Interpreted by ECDC, as for Austria | |
Malta | ● | ● | DLG/DD/DL | SIR | EUCAST CB 2014 | |||
Netherlands | ● | ● | ● | DD/DL | SIR | Survey in 12 clinical labs in NL in 2009 (Ned Tijdschr Med Microbiol 2009;17:nr1) | ||
Norway | ● | ● | ● | ● | DL | Q | Interpreted by ECDC, as for Austria | |
Portugal | ● | ● | ● | ● | DD | Q | Interpreted by ECDC, as for Austria | |
Romania | ● | ● | ● | ● | ● | DD | Q | Interpreted by ECDC, as for Austria |
Slovakia | ● | ● | ● | ● | ● | DL | SIR | In 2013, CLSI CB |
Slovenia | ● | ● | ● | DD | Q | Interpreted by ECDC, as for Austria | ||
Spain | ● | ● | ● | ● | ● | DLG | Q | Interpreted by ECDC, as for Austria |
United Kingdom | ● | ● | ● | DD/DL/DLG | SIR | Varies depending on clinical microbiology laboratory |
MSs: Member States; AST: antimicrobial susceptibility testing; DD: disk diffusion; DL: dilution; DLG: dilution with gradient strip; Q: quantitative data; SIR: susceptible, intermediate, resistant (categorical data); ECDC: European Centre for Disease Prevention and Control; EUCAST: European Committee on Antimicrobial Susceptibility Testing; CA‐SFM: French Society for Microbiology; ECOFF: epidemiological cut‐off; CBP: clinical breakpoint; CIP: ciprofloxacin; ERY: erythromycin; GEN: gentamicin; TET: tetracycline; AMC: amoxicillin/clavulanate.
Antimicrobials tested.